Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022 –2031
ConclusionsCVD in people with type 2 diabetes will substantially impact the Australian healthcare system and society over the next decade. Future work to investigate different strategies to optimize the control of risk factors for the prevention and treatment of CVD in type 2 diabetes in Australia is warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 21, 2023 Category: Health Management Source Type: research
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
AbstractUncertainty assessment is a cornerstone in model-based health economic evaluations (HEEs) that inform reimbursement decisions. No comprehensive overview of available uncertainty assessment methods currently exists. We aimed to review methods for uncertainty assessment for use in model-based HEEs, by conducting a snowballing review. We categorised all methods according to their stage of use relating to uncertainty assessment (identification, analysis, communication). Additionally, we classified identification methods according to sources of uncertainty, and subdivided analysis and communication methods according to ...
Source: PharmacoEconomics - March 21, 2023 Category: Health Management Source Type: research
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022 –2031
ConclusionsCVD in people with type 2 diabetes will substantially impact the Australian healthcare system and society over the next decade. Future work to investigate different strategies to optimize the control of risk factors for the prevention and treatment of CVD in type 2 diabetes in Australia is warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 21, 2023 Category: Health Management Source Type: research
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
AbstractUncertainty assessment is a cornerstone in model-based health economic evaluations (HEEs) that inform reimbursement decisions. No comprehensive overview of available uncertainty assessment methods currently exists. We aimed to review methods for uncertainty assessment for use in model-based HEEs, by conducting a snowballing review. We categorised all methods according to their stage of use relating to uncertainty assessment (identification, analysis, communication). Additionally, we classified identification methods according to sources of uncertainty, and subdivided analysis and communication methods according to ...
Source: PharmacoEconomics - March 21, 2023 Category: Health Management Source Type: research
Economic Impact of Insufficient and Disturbed Sleep in the Workplace
ConclusionsThis review synthesizes the existing data regarding the negative impacts of insufficient and disturbed sleep on the workplace, suggesting that employers have an economic stake in their employees ’ sleep.Trial RegistrationPROSPERO: CRD42021224212. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 18, 2023 Category: Health Management Source Type: research
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
(Source: PharmacoEconomics)
Source: PharmacoEconomics - March 16, 2023 Category: Health Management Source Type: research
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2 − Metastatic Breast Cancer in Postmenopausal Women in the USA
ConclusionsAt a willingness to pay of $100,000/QALY gained, our model predicts that combining CDK4/6 inhibitors plus letrozole is not cost effective with a marginal increase in QALYs at a high cost. Lowering the cost of these drugs or identifying patients who can receive maximal benefit from CDK4/6 inhibitors would improve the value of this regimen in patients. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 15, 2023 Category: Health Management Source Type: research
Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward
ConclusionsDespite a large body of health economics evidence on non-surgical biomedical HIV prevention technologies, important gaps in the scope of evidence and methodology remain. To ensure that high-quality research influences key decision-making junctures and facilitates the delivery of prevention products in a way that maximises impact, we make five broad recommendations related to: improved study design, an increased focus on service delivery, greater community and stakeholder engagement, the fostering of an active network of partners across sectors and an enhanced application of research. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review
ConclusionThe net health impact of constraints is vital evidence to help decision-makers scale up the delivery of cell and gene therapies as patient volume increases and more advanced therapy medicinal products are launched. CEAs will be essential to quantify how constraints affect the cost-effectiveness of care, prioritise constraints to be resolved, and establish the value of strategies to implement cell and gene therapies by accounting for their health opportunity cost. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward
ConclusionsDespite a large body of health economics evidence on non-surgical biomedical HIV prevention technologies, important gaps in the scope of evidence and methodology remain. To ensure that high-quality research influences key decision-making junctures and facilitates the delivery of prevention products in a way that maximises impact, we make five broad recommendations related to: improved study design, an increased focus on service delivery, greater community and stakeholder engagement, the fostering of an active network of partners across sectors and an enhanced application of research. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review
ConclusionThe net health impact of constraints is vital evidence to help decision-makers scale up the delivery of cell and gene therapies as patient volume increases and more advanced therapy medicinal products are launched. CEAs will be essential to quantify how constraints affect the cost-effectiveness of care, prioritise constraints to be resolved, and establish the value of strategies to implement cell and gene therapies by accounting for their health opportunity cost. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review
ConclusionsOverall, this review found mixed evidence on the cost effectiveness of depression treatment choices among LMICs, with some indication that task sharing with lay health workers may be cost effective. Future research will be needed to fill the gaps around the cost effectiveness of depression treatments in younger people and beyond healthcare facilities. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 9, 2023 Category: Health Management Source Type: research
